secwatch.observer — SEC 8-K summary
======================================

Issuer:     BiomX Inc. (PHGE)
CIK:        0001739174
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001213900-25-017728
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BiomX raises $12M in combined offerings; funds BX004 Phase 2b to Q1 2026
------------------------------------------------------------------------

- Gross proceeds ~$12M from registered direct offering, private placement, and warrant exercise at $0.9306/share.
- Investors include Deerfield Management, Cystic Fibrosis Foundation, and Nantahala Capital.
- Proceeds to fund BX004 Phase 2b in CF; topline results expected Q1 2026.
- Existing warrants reduced from $2.311 to $0.9306; new warrants issued for 100% of exercised shares.
- Also advancing BX211 Phase 2 readout in diabetic foot osteomyelitis this quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739174/000121390025017728/0001213900-25-017728-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739174/000121390025017728/ea0232201-8k_biomx.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-017728

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer